Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
Leishmaniasis is one of the major neglected tropical diseases of the world. Druggable targets are the parasites’ cysteine proteases (CPs) of clan CA, family C1 (CAC1). In previous studies we identified two peptidomimetic compounds, the aziridine-2,3-dicarboxylates 13b and 13e, out of a series of inh...
Guardat en:
| Publicat: |
2016
|
|---|---|
| Matèries: | |
| Accés en línia: | http://hdl.handle.net/10872/13968 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|